Vourlekis Jason S, Schwarz Marvin I, Cherniack Reuben M, Curran-Everett Douglas, Cool Carlyne D, Tuder Rubin M, King Talmadge E, Brown Kevin K
Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
Am J Med. 2004 May 15;116(10):662-8. doi: 10.1016/j.amjmed.2003.12.030.
To determine the effect of pulmonary fibrosis on survival in an unselected group of patients with hypersensitivity pneumonitis.
We identified 72 patients with hypersensitivity pneumonitis confirmed by surgical lung biopsy in the database of the Clinical Interstitial Lung Disease Program at the National Jewish Medical and Research Center. All biopsy specimens were scored according to the presence or absence of fibrosis. Comparisons were made between patients with (fibrotic group) and without (nonfibrotic group) pathologic fibrosis. Vital status was ascertained and Kaplan-Meier curves were plotted. Cox regression analysis was used to determine predictors of survival.
Forty-six patients were classified as fibrotic and 26 as nonfibrotic. Twenty-nine percent had exposure to a bird antigen, 33% had exposure to a microbial antigen, and 38% had unknown exposure. Patients with fibrosis were significantly older, showed greater restrictive lung physiology, and had greater all-cause and respiratory mortality. Median survival in fibrotic patients was 7.1 years, which was significantly less than survival in those without fibrosis. In an age-adjusted regression analysis, antigen class, symptom duration, and lung function had no effect on survival. Only the presence of pathologic fibrosis was predictive of increased mortality (hazard ratio = 6.01; 95% confidence interval: 1.68 to 21.45; P = 0.006).
Pulmonary fibrosis is associated with diminished survival in patients with hypersensitivity pneumonitis.
确定肺纤维化对一组未经选择的过敏性肺炎患者生存的影响。
我们在国家犹太医学与研究中心临床间质性肺病项目数据库中,识别出72例经外科肺活检确诊为过敏性肺炎的患者。所有活检标本根据有无纤维化进行评分。对有病理纤维化(纤维化组)和无病理纤维化(非纤维化组)的患者进行比较。确定生存状态并绘制Kaplan-Meier曲线。采用Cox回归分析确定生存预测因素。
46例患者被分类为纤维化,26例为非纤维化。29%接触鸟类抗原,33%接触微生物抗原,38%接触情况不明。纤维化患者年龄显著更大,肺限制性生理学表现更明显,全因死亡率和呼吸死亡率更高。纤维化患者的中位生存期为7.1年,显著短于无纤维化患者。在年龄校正回归分析中,抗原类别、症状持续时间和肺功能对生存无影响。只有病理纤维化的存在可预测死亡率增加(风险比=6.01;95%置信区间:1.68至21.45;P=0.006)。
肺纤维化与过敏性肺炎患者生存率降低相关。